Denise M. Boudreau, RPh, PhD

Associate Investigator

206-287-2067

boudreau.d@ghc.org

Recent publications

Curriculum vitae (CV)

 

 

 

 

 

Research interests and experience

  • Medication use & patient safety: general drug safety research; pharmaco-epidemiology; observational study research methods; active surveillance on the safety of pharmaceuticals; validation of pharmacy data sources; pharmacy practice research
  • Health services & economics: pharmaceutical outcomes research; cost-effectiveness analysis; impact of benefit designs on clinical and economic endpoints; burden of illness
  • Cancer control: clinical and biologic effect of commonly used medications on cancer risk and outcomes; cost-effectiveness of chemotherapy

Pharmaco-epidemiologist Denise Boudreau plays an integral role in Group Health Research Institute (GHRI) investigations into medication safety and cost-effectiveness of pharmaceuticals. Known at the Institute for her expertise in pharmaco-epidemiologic methods, she has diverse experience spanning pharmacies, classrooms, and research institutions.

Dr. Boudreau worked as a pharmacist and research associate for six years before earning her PhD from the Pharmaceutical Outcomes and Research Policy Program at the University of Washington (UW) in 2002. She began her career at GHRI in 2003 as a research associate and was promoted to assistant investigator just two years later. Dr. Boudreau is an associate affiliate professor in the UW School of Pharmacy and has co-led their pharmaco-epidemiology course since 2008. She also serves on several student thesis and dissertation committees.

Dr. Boudreau is adept at working with automated health plan data and has expertise in observational study design, managed care, drug safety, and economic evaluation. She brings an in-depth working knowledge of Group Health pharmacy data and practices to her research, which ranges from cancer to cardiovascular disease to opioid use. The principal investigator on several studies looking at the link between prescription medications and both cancer risk and outcomes—such as news-making statins—her latest project explores the influence of commonly used medications such as statins and antidepressants on breast cancer recurrence.

Among her newest areas of interest is opioid use and misuse—including investigating trends and risks of long-term use to manage chronic pain. A veteran contributor to the HMO Research Network Center for Education & Research on Therapeutics (CERT) studies, Dr. Boudreau is also an expert at pharmaco-economic studies—looking, for example, at the costs and effects of using medications on biologic and screening endpoints for breast cancer and the economic burden of risk factors for metabolic syndrome.

Dr. Boudreau’s research has been exhibited internationally at conferences such as the International Society for Pharmacoepidemiology, the International Society for Pharmacoeconomics and Outcomes Research, and the Congress of Epidemiology. Her professional memberships include the International Society for Pharmacoepidemiology and the International Society for Pharmacoeconomics and Outcomes Research. She retains her pharmacy license in Washington and Rhode Island.

Related information:

Top

Recent publications

Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011; 306(24):doi:10.1001/ jama.2011.1830 PubMed

Andrade SE, Moore Simas TA, Boudreau D, Raebel MA, Toh S, Syat B, Dashevsky I, Platt R. Validation of algorithms to ascertain clinical conditions and medical procedures used during pregnancy. Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1168-76. doi: 10.1002/pds.2217. Epub 2011 Aug 22. PubMed

Boudreau DM, Yu O, Gray SL, Raebel MA, Johnson J, Larson EB. Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. J Am Geriatr Soc. 2011 Nov;59(11):2069-76. doi: 10.1111/j.1532-5415.2011.03654.x. Epub 2011 Oct 22.

Campbell CI, Weisner C, Leresche L, Ray GT, Saunders K, Sullivan MD, Banta-Green CJ, Merrill JO, Silverberg MJ, Boudreau D, Satre DD, Von Korff M. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health. 2010 Dec;100(12):2541-7. Epub 2010 Aug 19. PubMed

Chubak J, Boudreau DM, Fishman PA, Elmore JG. Cost of breast-related care in the year following false positive screening mammograms. Med Care. 2010;48(9):815-20. PubMed

Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010 Jul;9(4):603-21. Epub 2010 Apr 9. PubMed

Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to antidepressant medication use. Int J Cancer. 2011 Jan 1;128(1):227-32. Epub 2010 Mar 15. doi: 10.1002/ijc.25322. PubMed

Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010 Jan;137(1):13-9. Epub 2009 Apr 10. PubMed

Malone DC, Boudreau DM, Nichols GA, Raebel MA, Fishman PA, Feldstein AC, Ben-Joseph RH, Okamoto LJ, Boscoe AN, Magid DJ. Association of cardiometabolic risk factors and prevalent cardiovascular events. Metab Syndr Relat Disord. 2009;7(6):585-93. Epub 2009 Nov 9. PubMed

Boudreau D, Von Korff M, Rutter CM, Saunders K, Ray GT, Sullivan MD, Campbell CI, Merrill JO, Silverberg MJ, Banta-Green C, Weisner C. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166-1175. PubMed

To view more publications, please see Dr. Boudreau's CV.

Top